TACE plus RFA extends survival in liver cancer patients

April 9, 2008 TACE plus RFA extends survival in liver cancer patients Shalmali Pal -------------------------------------------------------------------------------- Pairing chemoembolization with radiofrequency ablation improved survival in patients with unresectable hepatocellular cancer, according to a multidisciplinary group based at Shangdong University in Jinan, China. Their study results demonstrated how tumor microarchitecture could be manipulated to boost localized therapy. Transcatheter arterial chemoembolization (TACE) slows tumor blood flow while RFA shrinks uninodular tumors, but neither technique by itself offers adequate control for tumors larger than 3 cm, wrote Dr. Bao-Quan Cheng, Ph.D., and colleagues in the Journal of the American Medical Association.

See full article and related articles at DiagnosticImaging.com
This article was republished with permission from CMPMedica, LLC